MacroGenics (MGNX)

• Market cap: $86M
• 1 day: -5.56%
• 5 days: -15%
• 1 month: -22.73%
• 3 months: -15.53%
• 6 months: -7.48%
• Year to date: -58.79%
• 1 year: -67.54%
• 5 years: -93.13%
• 10 years: -95.78%
• Sector: Healthcare
• Industry: Biotechnology

About: Macrogenics Inc is a biotechnology company focused on discovering and developing antibody-based therapeutics for the treatment of cancer. Its product includes MARGENZA, which is for the treatment of adult patients with metastatic HER2-positive breast cancer. It's a pipeline of product candidates designed to target either various tumor-associated antigens or immune checkpoint molecules. The company has three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload.

Employees: 341